Literature DB >> 22192320

Evidence-based venous thromboembolism prophylaxis is associated with a six-fold decrease in numbers of symptomatic venous thromboembolisms in rehabilitation inpatients.

R Samuel Mayer1, Michael B Streiff, Deborah B Hobson, Daniel E Halpert, Sean M Berenholtz.   

Abstract

OBJECTIVES: To measure the impact of a standardized risk assessment tool and specialty-specific, risk-adjusted venous thromboembolism (VTE) order sets on compliance with American College of Chest Physicians (ACCP) guidelines and the number of symptomatic VTE as assessed by administrative data.
DESIGN: Prospective cohort study.
SETTING: Academic hospital inpatient rehabilitation unit. PATIENTS AND PARTICIPANTS: All patients on the rehabilitation unit. METHODS AND
INTERVENTIONS: Assessment of VTE risk factors and evaluated admission VTE prophylaxis orders before and after implementation of an ACCP guideline-based, specialty-specific VTE risk assessment, and prophylaxis order set by using a standardized data collection form. MAIN OUTCOME MEASURES: Discharge diagnostic codes for VTE and pulmonary embolism were tracked by ICD-9 (International Classification of Diseases, 9th edition) discharge diagnosis codes for the 12 months before and 36 months after the intervention.
RESULTS: Before implementation of the VTE order set, 27% of patients received VTE prophylaxis in compliance with the 2004 ACCP VTE guidelines. By following implementation of specialty-specific, risk-adjusted VTE order sets, compliance increased to 98%. In the year before VTE order-set implementation, the number of VTEs per admission was 49 per 1000. By following implementation, the number of VTEs steadily decreased each year to 8 per 1000 in 2007 (χ(2) = 14.985; P = .0001).
CONCLUSIONS: Implementation of a standardized VTE risk assessment tool and prophylaxis order set resulted in a substantial improvement in compliance with ACCP guidelines for VTE prophylaxis and was associated with a 6-fold reduction in the number of symptomatic VTEs in a hospital-based rehabilitation unit.
Copyright © 2011 American Academy of Physical Medicine and Rehabilitation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22192320     DOI: 10.1016/j.pmrj.2011.07.022

Source DB:  PubMed          Journal:  PM R        ISSN: 1934-1482            Impact factor:   2.298


  4 in total

1.  Minor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease.

Authors:  Adam S Faye; Kenneth W Hung; Kimberly Cheng; John W Blackett; Anna Sophia Mckenney; Adam R Pont; Jianhua Li; Garrett Lawlor; Benjamin Lebwohl; Daniel E Freedberg
Journal:  Inflamm Bowel Dis       Date:  2020-08-20       Impact factor: 5.325

2.  Discovery of novel plasma biomarkers for future incident venous thromboembolism by untargeted synchronous precursor selection mass spectrometry proteomics.

Authors:  S B Jensen; K Hindberg; T Solomon; E N Smith; J D Lapek; D J Gonzalez; N Latysheva; K A Frazer; S K Braekkan; J-B Hansen
Journal:  J Thromb Haemost       Date:  2018-08-06       Impact factor: 5.824

Review 3.  Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.

Authors:  Christina L Fanola
Journal:  Vasc Health Risk Manag       Date:  2015-05-27

Review 4.  An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes.

Authors:  Christina L Cove; Elaine M Hylek
Journal:  J Am Heart Assoc       Date:  2013-10-23       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.